Paliperidone palmitate versus oral antipsychotics in recently diagnosed schizophrenia
A. Schreiner(Janssen (Germany)), L. Hargarter(Janssen (Germany)), Adam Janik(Janssen (United States)), Philip Gorwood(Inserm), Mathias Zink(Central Institute of Mental Health), P. Chérubin(Janssen (France)), Kaire Aadamsoo(North Estonia Medical Centre), Alp Üçok(Centre for Addiction and Mental Health), Marjolein Lahaye(Janssen (Netherlands)), Nikolaj G. Neznanov(St.Petersburg V.M.Bekhterev Psychoneurological Research Institute), Juan Schronen(Health & Medical Publishing Group), A.C. Altamura(University of Milan), Manuel Franco(Instituto de Investigación Biomédica de Salamanca)
Cited by 143
Related Papers
How mental health care should change as a consequence of the COVID-19 pandemic
|The Lancet Psychiatry|2020|1.9k
Cognitive dysfunction in psychiatric disorders: characteristics, causes and the quest for improved therapy
|Nature Reviews Drug Discovery|2012|1.3k
The consequences of the COVID-19 pandemic on mental health and implications for clinical practice
|European Psychiatry|2020|1.2k
Treatment-Resistant Schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) Working Group Consensus Guidelines on Diagnosis and Terminology
|American Journal of Psychiatry|2016|1.1k